⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CERO News
CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
globenewswire.com
CERO
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
globenewswire.com
SRXH
CERO
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
globenewswire.com
CERO
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
globenewswire.com
SRXH
CERO
Form 8-K
sec.gov
CERO
CEROW
Form 8-K
sec.gov
CERO
CEROW
Form 8-K
sec.gov
CEROW
CERO
Form 8-K
sec.gov
OVID
CERO
Form 8-K
sec.gov
CERO
CEROW
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
globenewswire.com
CERO